The winter holidays and the New Year are approaching. There are multi-hued lights, decorated trees, candles, menorahs, holiday music and wreathes. This is also the time of the year for television, mail, radio and other requests for contributions to various…
I was in Tennessee this week, seeing the colors of the trees burn across the ridges, and feeling the fall induced opportunity to feel gratitude. As you get this, we’ll all be deep into the holidays and winter, giving us…
Did you know that it takes an average of $800 Million and 8 years for a drug manufacturer to complete research and development, prove safety and efficacy in multiple clinical trials? (read more at http://bit.ly/6wMxgk) More so, in the arena…
What could be done to prevent another Vioxx? This pain medication for arthritis became a blockbuster after its introduction in 1999, only to be taken off the market in 2004 when a study linked the drug to an increased risk…
DeCode Genetics, a pioneering company that used the Icelandic population as its guinea pigs in detecting disease-causing mutations, filed for bankruptcy on Tuesday.
Durham, N.C. — Dermatologists at Duke University using rituximab (Rituxan, Genentech) for the management of patients with treatment-resistant bullous pemphigoid (BP) have found that this anti-CD20 monoclonal antibody allows corticosteroid-dependent patients to successfully taper their immunosuppressive therapy.
Autoimmune bullous diseases are a heterogeneous group of disorders that can be subdivided according to the level of split formation in the intraepidermal blistering pemphigus diseases and subepidermal bullous disorders.
